Compare Dollar General Corp. (DG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Twist Bioscience Corp — how do they compare? Dollar General Corp. trades at $123.69 (market cap $27.42B), while Twist Bioscience Corp trades at $159.69 (market cap $10.08B). The key difference: Dollar General Corp. is far larger — about 2.7× Twist Bioscience Corp's market cap, and Dollar General Corp. pays a 1.9% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Twist Bioscience Corp for 27 Days on average.
| DG | TWST | |
|---|---|---|
Market Cap | $27.42B | $10.08B |
Volume | 2,291,517 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $205.00 |
52-Week Low | $95.94 | $25.45 |
Typical Hold Time | 59 Days | 27 Days |
Enterprise Value | $41.60B | $10.01B |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $122.16, down 0.89% on the day, with a neutral technical signal. The stock shows strong fundamentals with a P/E of 16.14 and P/S of 0.63, indicating potential undervaluation. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $2.48 surpassing the $2.01 expectation. Positive news includes tariff refunds boosting margins and expansion of same-day delivery via Instacart, supporting growth initiatives.
The outlook is cautiously optimistic, with a consensus price target of $137.27 offering ~12% upside. Key opportunities include margin improvement from operational initiatives, while risks involve competitive pressures and potential consumer spending softness. Analyst sentiment is predominantly buy-rated (55.77%), though recent insider selling and mixed technical indicators warrant monitoring.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
